$50,000 award will grant access to LabCentral's lab space, shared resources, and community to one early-stage biotech company working to treat or cure type 1 diabetes. As part of a first-of-its-kind ...
Enveric Biosciences has presented research highlighting the its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. EB-003 is a neuropathogenic and non-hallucinogenic N, ...
Breakthrough T1D invites early-stage companies pursuing research relevant to Disease Modifying Therapies (DMT) and Cell Therapies (CT) research strategies to apply for the Breakthrough T1D Golden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback